Search for content, post, videos

Biotech Stocks That Should Be On Your Watch List: Aduro BioTech Inc (ADRO), Hemispherx BioPharma, Inc (HEB), Uniqure NV (QURE)

Hemispherx BioPharma, Inc (NYSEMKT:HEB) declined 8.12% to end last trading session at $0.0735. The company on Nov. 17, 2015 announced its financial results for the nine months ended September 30, 2015. The net loss (including non-cash effects) was approximately $12,093,000 or $(0.05) per share as compared to a net loss of $12,994,000 or ($0.07) per share for the same nine month period in 2014.

Cash, cash equivalents and marketable securities were approximately $12,375,000 at September 30, 2015 as compared to $16,108,000 as of December 31, 2014.

On September 28, 2015, the Company announced formal granting of a new composition of matter patent by the European Patent Office on Ampligen which may extend through year 2029 and potentially beyond. This important milestone was achieved through the efforts of William A. Carter, the company’s Chairman and CEO, leading a research team at the company’s wholly owned R and D laboratories in New Brunswick, NJ. The patents are expected to be issued in up to 25 countries.

Uniqure NV (NASDAQ:QURE) plunged 8.05% to finish last trading session at $16.00. The company on Dec. 18, 2015 announced the appointment of Dan Soland as the new Chief Executive Officer of the Company. Mr. Soland will succeed Jorn Aldag, who has decided to step down as CEO, a role he has held since 2009. Mr. Soland will also be nominated for appointment to uniQure’s Management Board, subject to approval by the Company’s General Meeting of Shareholders. Mr. Aldag will be available to assist the Company during the transition.

Mr. Soland, 57, brings to uniQure more than 30 years of industry experience, most recently serving as Vice President and Chief Operating Officer of ViroPharma. At ViroPharma, Mr. Soland was responsible for building the company’s organization and commercial infrastructure until its successful sale to Shire in 2014 for approximately $4 billion. Mr. Soland was previously President of Chiron Vaccines, where he helped engineer a turnaround that contributed to Chiron’s acquisition by Novartis. Earlier, he was President and CEO of Epigenesis Pharmaceuticals and Vice President and Director of Worldwide Marketing Operations at GlaxoSmithKline Biologicals and held positions of increasing responsibility at Pasteur-Merieux’s Connaught Laboratories (now Sanofi Pasteur). Mr. Soland holds a B.S. in Pharmacy from the University of Iowa.

Aduro BioTech Inc (NASDAQ:ADRO) decreased 6.87% to complete last trading session at $29.56. The company on Dec. 16, 2015 announced that it has received a milestone payment from Janssen Biotech, Inc. for the acceptance of an Investigational New Drug (IND) Application by the U.S. Food and Drug Administration for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. Janssen, Aduro’s license partner for ADU-741, plans to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 by the end of 2015.

“We are extremely pleased with the progress Janssen has made with the development of ADU-741,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “In addition to FDA acceptance of INDs for ADU-741 and ADU-214 in the past two months, we recently received clearance from the FDA for our IND in which we are collaborating with Incyte to begin a clinical trial evaluating the combination of CRS-207 and epacadostat in patients with platinum-resistant ovarian, fallopian and peritoneal cancer. We are thrilled to work with top-notch collaborators like Janssen, Novartis and Incyte, which share the same dedication to the development of novel therapies for patients who need it the most.”